

PCT / CA 99/01177

10 JANUARY 2000 (10.01.00)

cagg/1177  
EJV

REC'D 18 JAN 2000

WIPO

PCT

PA 185900

# THE UNITED STATES OF AMERICA

**TO ALL TO WHOM THESE PRESENTS SHALL COME:**

**UNITED STATES DEPARTMENT OF COMMERCE**

**United States Patent and Trademark Office**

**December 15, 1999**

**THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM  
THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK  
OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT  
APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A  
FILING DATE UNDER 35 USC 111.**

**APPLICATION NUMBER: 60/111,794**

**FILING DATE: December 11, 1998**

## **PRIORITY DOCUMENT**

SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)



**By Authority of the  
COMMISSIONER OF PATENTS AND TRADEMARKS**

**H. PHILLIPS**  
Certifying Officer

12/11/98  
1471 U.S. PTO

Please type a plus sign (+) inside this box →

PTO/SB/16 (2-98)

Approved for use through 01/31/2001 OMB 0651-0037  
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53 (c).


jc541 U.S. PTO  
60/111794  
12/11/98

12/11/98

INVENTOR(S)		
Given Name (first and middle [if any])	Family Name or Surname	Residence (City and either State or Foreign Country)
Robert	Shipman	Mississauga, Canada
<input type="checkbox"/> Additional inventors are being named on the _____ separately numbered sheets attached hereto		
TITLE OF THE INVENTION (280 characters max)		
Method and Kit for the Characterization of Antibiotic-Resistance Mutations in Mycobacterium tuberculosis		
Direct all correspondence to:		
<input type="checkbox"/> Customer Number	<input type="text"/> → 	
OR		
<input type="checkbox"/> Firm or Individual Name	Oppedahl & larson, LLP	
Address	PO Box 5270	
Address	611 Main Street	
City	Frisco	State: CO ZIP: 80443-5270
Country	US	Telephone: 970 668 2050 Fax: 970 668 2082
ENCLOSED APPLICATION PARTS (check all that apply)		
<input checked="" type="checkbox"/> Specification Number of Pages	20	<input type="checkbox"/> Small Entity Statement
<input checked="" type="checkbox"/> Drawing(s) Number of Sheets	2	<input type="checkbox"/> Other (specify) <input type="text"/>
METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT (check one)		
<input checked="" type="checkbox"/> A check or money order is enclosed to cover the filing fees	FILING FEE AMOUNT (\$)	
<input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number: 15-0610	150.00	
The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.		
<input checked="" type="checkbox"/> No		
<input type="checkbox"/> Yes, the name of the U.S. Government agency and the Government contract number are: _____		

Respectfully submitted,

SIGNATURE

  
Marina T. Larson

TYPED or PRINTED NAME

Marina T. Larson

TELEPHONE

970 668 2050

Date

12/11/98

REGISTRATION NO.

32,038

(if appropriate)

Docket Number:

VENP055PV

## USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT

This collection of information is required by 37 CFR 1.51. The information is used by the public to file (and by the PTO to process) a provisional application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 8 hours to complete, including gathering, preparing, and submitting the complete provisional application to the PTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C., 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Box Provisional Application, Assistant Commissioner for Patents, Washington, D.C., 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**FEE TRANSMITTAL**

Patent fees are subject to annual revision on October 1.

These are the fees effective October 1, 1997.

Small Entity payments must be supported by a small entity statement, otherwise large entity fees must be paid. See Forms PTO/SB/09-12. See 37 C.F.R. §§ 1.27 and 1.28.

TOTAL AMOUNT OF PAYMENT (\$ 150.00


**Complete if Known**

Application Number	TO BE ASSIGNED
Filing Date	11 DECEMBER 1998
First Named Inventor	SHIPMAN, ROBERT
Examiner Name	N/A
Group / Art Unit	N/A
Attorney Docket No.	VGENP055PV

METHOD OF PAYMENT (check one)		FEE CALCULATION (continued)																																																																																																																																																																																											
<p>1. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge indicated fees and credit any over payments to:</p> <p>Deposit Account Number <b>15-0610</b></p> <p>Deposit Account Name <b>OPPEDAHL &amp; LARSON</b></p> <p><input checked="" type="checkbox"/> Charge Any Additional Fee Required Under 37 C.F.R. §§ 1.16 and 1.17      <input type="checkbox"/> Charge the Issue Fee Set in 37 C.F.R. § 1.18 at the Mading of the Notice of Allowance</p>		<p>3. ADDITIONAL FEES</p> <table border="1"> <thead> <tr> <th>Large Entity</th> <th>Small Entity</th> <th>Fee Code (\$)</th> <th>Fee Code (\$)</th> <th>Fee Description</th> <th>Fee Paid</th> </tr> </thead> <tbody> <tr><td>105</td><td>130</td><td>205</td><td>65</td><td>Surcharge - late filing fee or oath</td><td></td></tr> <tr><td>127</td><td>50</td><td>227</td><td>25</td><td>Surcharge - late provisional filing fee or cover sheet</td><td></td></tr> <tr><td>139</td><td>130</td><td>139</td><td>130</td><td>Non-English specification</td><td></td></tr> <tr><td>147</td><td>2,520</td><td>147</td><td>2,520</td><td>For filing a request for reexamination</td><td></td></tr> <tr><td>112</td><td>920*</td><td>112</td><td>920*</td><td>Requesting publication of SIR prior to Examiner action</td><td></td></tr> <tr><td>113</td><td>1,840*</td><td>113</td><td>1,840*</td><td>Requesting publication of SIR after Examiner action</td><td></td></tr> <tr><td>115</td><td>110</td><td>215</td><td>55</td><td>Extension for reply within first month</td><td></td></tr> <tr><td>116</td><td>400</td><td>216</td><td>200</td><td>Extension for reply within second month</td><td></td></tr> <tr><td>117</td><td>950</td><td>217</td><td>475</td><td>Extension for reply within third month</td><td></td></tr> <tr><td>118</td><td>1,510</td><td>218</td><td>755</td><td>Extension for reply within fourth month</td><td></td></tr> <tr><td>128</td><td>2,060</td><td>228</td><td>1,030</td><td>Extension for reply within fifth month</td><td></td></tr> <tr><td>119</td><td>310</td><td>219</td><td>155</td><td>Notice of Appeal</td><td></td></tr> <tr><td>120</td><td>310</td><td>220</td><td>155</td><td>Filing a brief in support of an appeal</td><td></td></tr> <tr><td>121</td><td>270</td><td>221</td><td>135</td><td>Request for oral hearing</td><td></td></tr> <tr><td>138</td><td>1,510</td><td>138</td><td>1,510</td><td>Petition to institute a public use proceeding</td><td></td></tr> <tr><td>140</td><td>110</td><td>240</td><td>55</td><td>Petition to revive - unavoidable</td><td></td></tr> <tr><td>141</td><td>1,320</td><td>241</td><td>660</td><td>Petition to revive - unintentional</td><td></td></tr> <tr><td>142</td><td>1,320</td><td>242</td><td>660</td><td>Utility issue fee (or reissue)</td><td></td></tr> <tr><td>143</td><td>450</td><td>243</td><td>225</td><td>Design issue fee</td><td></td></tr> <tr><td>144</td><td>670</td><td>244</td><td>335</td><td>Plant issue fee</td><td></td></tr> <tr><td>122</td><td>130</td><td>122</td><td>130</td><td>Petitions to the Commissioner</td><td></td></tr> <tr><td>123</td><td>50</td><td>123</td><td>50</td><td>Petitions related to provisional applications</td><td></td></tr> <tr><td>126</td><td>240</td><td>126</td><td>240</td><td>Submission of Information Disclosure Stmt</td><td></td></tr> <tr><td>581</td><td>40</td><td>581</td><td>40</td><td>Recording each patent assignment per property (times number of properties)</td><td></td></tr> <tr><td>146</td><td>790</td><td>246</td><td>395</td><td>Filing a submission after final rejection (37 CFR 1.129(a))</td><td></td></tr> <tr><td>149</td><td>790</td><td>248</td><td>395</td><td>For each additional invention to be examined (37 CFR 1.129(b))</td><td></td></tr> <tr><td colspan="4">Other fee (specify) _____</td><td colspan="2"></td></tr> <tr><td colspan="4">Other fee (specify) _____</td><td colspan="2"></td></tr> <tr> <td colspan="4">SUBTOTAL (2) (\$)</td> <td colspan="2">SUBTOTAL (3) (\$)</td> </tr> <tr> <td colspan="4">* Reduced by Basic Filing Fee Paid</td> <td colspan="2"></td> </tr> </tbody> </table>		Large Entity	Small Entity	Fee Code (\$)	Fee Code (\$)	Fee Description	Fee Paid	105	130	205	65	Surcharge - late filing fee or oath		127	50	227	25	Surcharge - late provisional filing fee or cover sheet		139	130	139	130	Non-English specification		147	2,520	147	2,520	For filing a request for reexamination		112	920*	112	920*	Requesting publication of SIR prior to Examiner action		113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action		115	110	215	55	Extension for reply within first month		116	400	216	200	Extension for reply within second month		117	950	217	475	Extension for reply within third month		118	1,510	218	755	Extension for reply within fourth month		128	2,060	228	1,030	Extension for reply within fifth month		119	310	219	155	Notice of Appeal		120	310	220	155	Filing a brief in support of an appeal		121	270	221	135	Request for oral hearing		138	1,510	138	1,510	Petition to institute a public use proceeding		140	110	240	55	Petition to revive - unavoidable		141	1,320	241	660	Petition to revive - unintentional		142	1,320	242	660	Utility issue fee (or reissue)		143	450	243	225	Design issue fee		144	670	244	335	Plant issue fee		122	130	122	130	Petitions to the Commissioner		123	50	123	50	Petitions related to provisional applications		126	240	126	240	Submission of Information Disclosure Stmt		581	40	581	40	Recording each patent assignment per property (times number of properties)		146	790	246	395	Filing a submission after final rejection (37 CFR 1.129(a))		149	790	248	395	For each additional invention to be examined (37 CFR 1.129(b))		Other fee (specify) _____						Other fee (specify) _____						SUBTOTAL (2) (\$)				SUBTOTAL (3) (\$)		* Reduced by Basic Filing Fee Paid					
Large Entity	Small Entity	Fee Code (\$)	Fee Code (\$)	Fee Description	Fee Paid																																																																																																																																																																																								
105	130	205	65	Surcharge - late filing fee or oath																																																																																																																																																																																									
127	50	227	25	Surcharge - late provisional filing fee or cover sheet																																																																																																																																																																																									
139	130	139	130	Non-English specification																																																																																																																																																																																									
147	2,520	147	2,520	For filing a request for reexamination																																																																																																																																																																																									
112	920*	112	920*	Requesting publication of SIR prior to Examiner action																																																																																																																																																																																									
113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action																																																																																																																																																																																									
115	110	215	55	Extension for reply within first month																																																																																																																																																																																									
116	400	216	200	Extension for reply within second month																																																																																																																																																																																									
117	950	217	475	Extension for reply within third month																																																																																																																																																																																									
118	1,510	218	755	Extension for reply within fourth month																																																																																																																																																																																									
128	2,060	228	1,030	Extension for reply within fifth month																																																																																																																																																																																									
119	310	219	155	Notice of Appeal																																																																																																																																																																																									
120	310	220	155	Filing a brief in support of an appeal																																																																																																																																																																																									
121	270	221	135	Request for oral hearing																																																																																																																																																																																									
138	1,510	138	1,510	Petition to institute a public use proceeding																																																																																																																																																																																									
140	110	240	55	Petition to revive - unavoidable																																																																																																																																																																																									
141	1,320	241	660	Petition to revive - unintentional																																																																																																																																																																																									
142	1,320	242	660	Utility issue fee (or reissue)																																																																																																																																																																																									
143	450	243	225	Design issue fee																																																																																																																																																																																									
144	670	244	335	Plant issue fee																																																																																																																																																																																									
122	130	122	130	Petitions to the Commissioner																																																																																																																																																																																									
123	50	123	50	Petitions related to provisional applications																																																																																																																																																																																									
126	240	126	240	Submission of Information Disclosure Stmt																																																																																																																																																																																									
581	40	581	40	Recording each patent assignment per property (times number of properties)																																																																																																																																																																																									
146	790	246	395	Filing a submission after final rejection (37 CFR 1.129(a))																																																																																																																																																																																									
149	790	248	395	For each additional invention to be examined (37 CFR 1.129(b))																																																																																																																																																																																									
Other fee (specify) _____																																																																																																																																																																																													
Other fee (specify) _____																																																																																																																																																																																													
SUBTOTAL (2) (\$)				SUBTOTAL (3) (\$)																																																																																																																																																																																									
* Reduced by Basic Filing Fee Paid																																																																																																																																																																																													
SUBMITTED BY		Complete (if applicable)																																																																																																																																																																																											
Typed or Printed Name	MARINA T. LARSON		Reg. Number	32,038																																																																																																																																																																																									
Signature	<i>Marina T. Larson</i>		Date	12/11/98																																																																																																																																																																																									
			Deposit Account User ID																																																																																																																																																																																										

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

12/11/98



U.S. Application No. : To be assigned  
Filing Date : December 11, 1998  
Application of: Shipman, Robert  
For: Method and Kit for the  
Characterization of Antibiotic-  
Resistance Mutations in  
Mycobacterium  
Attorney Docket No. : VGENP055PV

**Enclosures:**

- Provisional Patent Application Cover Sheet (PTO/SB/16)
- Fee Transmittal (PTO/SB/27)
- Check No. 004264 for \$150.00 *ck. No. 004549*
- Specification - 20 pages
- Drawings - 2 pages

Date: December 11, 1998

*Marina T. Larson*  
Marina T. Larson, Reg. No. 32,038  
Carl Oppedahl, Reg. No. 32,746  
OPPEDAHL & LARSON  
P.O. Box 5270  
Frisco, CO 80443-5270  
Tel: 970-668-2050  
Fax: 970-668-2082

**CERTIFICATE OF MAILING**

**CERTIFICATE OF EXPRESS MAIL UNDER 37 C.F.R. § 1.10**

"Express Mail" Mailing Label No. **EL139151914US**

**EL139151914US**

Date of Deposit December 11, 1998. I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service under 37 C.F.R. § 1.10 on the date indicated above and is addressed to:

Box Provisional Application  
Assistant Commissioner for Patents  
Washington, D.C. 20231

Mary Ann Healey  
(Type or print Name of person mailing paper or fee)

*Mary Ann Healey*  
(Signature of person mailing paper or fee)

*Pls see*

60111794-121108

**METHOD AND KIT FOR THE CHARACTERIZATION OF  
ANTIBIOTIC-RESISTANCE MUTATIONS IN  
*MYCOBACTERIUM TUBERCULOSIS***

**Background**

This application relates to a method and kit for the characterization of antibiotic resistance mutations in *Mycobacterium tuberculosis*, and particularly to the evaluation of such mutations in clinical samples.

*M. tuberculosis* can be resistant to all antibiotics that are currently used to treat tuberculosis patients. Antibiotic resistance is due to acquired point mutations in target genes in the genome of *M. tuberculosis*. These point mutations render the organism insensitive to the action of the antibiotic by preventing its uptake or activation, or by altering the antibiotic target. The observed antibiotic resistance in *M. tuberculosis* is not due to an episome-encoded resistance gene transferred from one strain to another and, like other bacteria, is single-step (one point mutation), high level resistance.

Rapid and accurate detection of antibiotic resistance in *Mycobacterium tuberculosis* in sputum samples would greatly improve both patient treatment and outcome. Presently, analysis of *M. tuberculosis* is carried out on DNA recovered from sputum samples handled according to Standard Infectious Disease/Public Health Laboratory practices. The sputum sample is decontaminated and a cell sediment isolated. This cell sediment is the sample source for all routine procedures used in the detection and isolation of *M. tuberculosis*. Portions of this sample are used in BacTec cultures for selective growth of *M. tuberculosis*, agar plate/agar slant cultures for *M. tuberculosis*, acid-fast bacilli (AFB) smears for mycobacteria detection and molecular

biological methods for the detection of *M. tuberculosis* and atypical mycobacteria. (See Fig. 1)

Mycobacterial DNA is prepared directly from the decontaminated sputum cell sediments according to standard procedures and this mycobacterial DNA is used in the various molecular biological detection procedures. The methods presently in use for the detection of *M. tuberculosis* are either PCR-based or probe-based. These tests are used primarily on AFB smear-positive samples. Since the presence of *M. tuberculosis* has already been established by the AFB smear, these tests are used primarily in a confirmatory capacity as opposed to a diagnostic capacity. Furthermore, these tests provide no information on the potential antibiotic resistance of these *M. tuberculosis* samples.

Below is a list of antibiotics used to treat *M. Tuberculosis* infections. The gene target of the specific antibiotic and regions associated with antibiotic resistance are listed, if known. The references on which the codon assignments are based are listed at the end of the application.

1.	Rifampin	rpoB gene	codon 504-531 <sup>a</sup>
2.	Isoniazid	katG gene	codon 275/315/328 <sup>b</sup>
3.	Isoniazid	fabG gene	unknown <sup>c</sup>
4.	Isoniazid	oxyR-ahpC intergenic region (PR)	codon 541-619 <sup>d</sup>
5.	Azithromycin	23S rRNA sequence nucleotide 2568A	<sup>e</sup>
6.	Pyrazinamide	pncA gene	codon 47/85 <sup>f</sup>
7.	Ethambutol	embB gene	codon 306 <sup>g</sup>
8.	Streptomycin	rpsL/s12 gene	codon 43/88 <sup>h</sup>

- |     |               |                  |                          |
|-----|---------------|------------------|--------------------------|
| 9.  | Streptomycin  | 16S/rrs sequence | unknown <sup>i</sup>     |
| 10. | Ciprofloxacin | gyrA gene        | codon 88-95 <sup>j</sup> |

Probe-based tests do exist for the determination of rifampin resistance in *M. tuberculosis* (line probe assay-InnoTek), but these probes rely on prior knowledge of antibiotic resistance-associated mutations in the *rpoB* gene. Mutations outside the region covered by the probe or new mutations not included in the probe cocktail could still confer resistance, but would not be detected using this product in it's present form.

Thus, there remains a need for a method for detecting antibiotic-resistance mutations in clinical *M. tuberculosis* sputum samples which is capable of detecting mutations in all of the gene targets which confer antibiotic resistance. It is an object of the present invention to provide such a method. It is a further object of this invention to provide amplification and cycle sequencing primer sets, and kits containing such primer sets, for use in the characterization of antibiotic resistance mutations in *M. tuberculosis*.

#### **Summary of Invention**

Amplification and cycle sequencing primer sets have been developed for the detection and analysis of antibiotic resistance-associated mutations in defined regions of the *rpoB* (rifampin), *katG* (isoniazid), *oxyR-ahpC PR* (isoniazid), *fabG* (isoniazid), *rpsL/s12* (streptomycin), 16S/rrs (streptomycin), *embB* (ethambutol), *pncA* (pyrazinamide), *gyrA* (ciprofloxacin) and 23S (azithromycin) genes. Using these primer sets and the OpenGene™ automated DNA sequencing system, a protocol has been developed which permits both the rapid identification of *M.tuberculosis* and the detection of antibiotic resistance-associated mutations in a series of gene targets. The

present invention uses a series of tests designed to detect antibiotic resistance-associated mutation in all gene targets for all antibiotics presently in use for the treatment of tuberculosis. The tests are employed in a hierarchical manner on both AFB smear-positive or smear-negative samples to determine both the presence and antibiotic-resistance of *M. tuberculosis* in a given sample. This method permits the simultaneous determination of *M. tuberculosis* presence in a sample and the antibiotic resistance profile to an entire panel of antibiotics. Standard methods require from 2-6 weeks to culture *M. tuberculosis* and additional time to establish antibiotic resistance. Although DNA sequence-based (genotypic) tests are not intended to replace the traditional culture-based (phenotypic) methods, these tests do represent a rapid, sensitive and accurate protocol which provides clinicians with valuable information regarding antibiotic treatment options within days as opposed to weeks.

#### **DESCRIPTION TO THE FIGURES**

Fig. 1 shows known testing protocols for *M. tuberculosis*; and

Fig. 2 shows a hierarchical assay scheme for evaluating *M. tuberculosis* type in accordance with the invention.

#### **DETAILED DESCRIPTION OF THE INVENTION**

In accordance with the invention, regions of the genome of *M. tuberculosis* associated with antibiotic resistance are amplified and sequenced using specifically designed amplification and sequencing primers. Various techniques for amplification are known, including the basic PCR amplification techniques described in US Patent No. 4,683,202, which is incorporated herein by reference. Similarly, various techniques for sequencing are known, some of which require prior amplification and some of which

do not. Included among known sequencing techniques are those disclosed in US Patents Nos. 5,834,189 and 5,789,168, which are incorporated herein by reference. The primers of the invention can be used in any of these sequencing formats, although the invention is exemplified below using separate amplification and cycle-sequencing steps.

In theory, the selection of primers to amplify and sequence a known region of interest should be straightforward. In fact, however, because of the possibility of primer binding to other sites, complications arising from secondary structure, and other factors which are not fully understood, some primers perform better than others for amplification and sequencing of the same region of interest. The present invention provides primers which have been optimized for the amplification and sequencing of regions associated with each of the ten known types of antibiotic resistance. These primer sets are shown below, along with the sequence of the genes that they are used to analyze. In the gene sequences, the locations of the primers are underlined.

### Primers

#### **rpoB (rifampin resistance)**

rpoB-F amplification primer, 20-mer, bp2201-2220 5' TAC GGT CGG CGA GCT GAT CC 3'

rpoB-R amplification primer, 20-mer, bp2611-2592 5' TAC GGC GTT TCG ATG AAC CC 3'

rpoB-5s sequencing primer, 20-mer, bp2201-2220 5' TAC GGT CGG CGA GCT GAT CC 3'

rpoB-3s sequencing primer, 20-mer, bp2611-2592 5' TAC GGC GTT TCG ATG AAC CC 3'

2161 aaaccgacga catcgaccac ttcggcaacc gccgcctgctacqgtcgac qaqctqatcc

2221 aaaaccagat ccgggtcggc atgtcgcgga tggagcggtt ggtccgggag cggatgacca

2281 cccaggacgt ggaggcgatc acaccgcaga cgttgatcaa catccggccg gtggtcggcg

2341 cgtatcaagga gttcttcggc accagccagc tgagccaatt catggaccag aacaacccgc

2401 tgtcggggtt gacccacaag cgccgactgt cggcgctggg gcccgccgt ctgtcacgtg

2461 agcgtgccgg gctggaggtc cgcgacgtgc acccgtcgca ctacggccgg atgtgccga  
2521 tcgaaacccc tgagggcccc aacatcggtc tgatcggtc gctgtcggtg tacgcgcggg  
2581 tcaaccgtt cggattcatc qaaacqccqt accgcaaggt ggtcgacggc gtggtagcg

**katG (isoniazid resistance)**

katG-F amplification primer, 20-mer, bp722-741 5' ATG GGG CTG ATC TAC GTG AA 3'  
katG-R amplification primer, 20-mer, bp1250-1231 5' GGT GTT CCA GCC AGC GAC GC 3'  
katG-5s sequencing primer, 20-mer, bp722-741 5' ATG GGG CTG ATC TAC GTG AA 3'  
katG-3s sequencing primer, 20-mer, bp1250-1231 5' GGT GTT CCA GCC AGC GAC GC 3'

661 gctcggcgat gagcgttaca gcgtaagcg ggatctggag aacccgctgg cccgggtgca  
721 gatggggctq atctacgtqa acccgagggg gccgaacggc aacccggacc ccatggccgc  
781 ggcggtcgac attcgcgaga cgtttcggcg catggccatg aacgacgtcg aaacagcggc  
841 gctgatcgtc ggcggtcaca ctttcggtaa gaccatggc gccggccgg ccgatcttgt  
901 cggccccgaa cccgaggctg cttcgctgga gcagatggc ttgggctgga agagctcgta  
961 tggcacccgaa acccgtaagg acgcgatcac acggccatc gaggtcgat ggacgaacac  
1021 cccgacgaaa tgggacaaca gttcctcgat gatcctgtac ggctacgagt gggagctgac  
1081 gaagagccct gctggcgctt ggcatacac cggcaaggac ggcggccggg ccggcaccat  
1141 cccggaccccg ttccggcgcc caggcgctc cccgacgatg ctggccactg acctctcgct  
1201 gccccgtggat ccgatctatg agcggatcac acgtcgctqq ctggaaacacc cccgaggaatt  
1261 ggcgcacgag ttccggcaagg cctggtacaa gctgatccac cgagacatgg gtcccggtgc

**oxyR-ahpC intergenic region (PR)**

PR-F amplification primer, 20-mer, bp451-470 5' ACC ACT GCT TTG CCG CCA CC 3'  
PR-R amplification primer, 20-mer, bp687-668 5' CCG ATG AGA GCG GTG AGC TG 3'  
PR-5s sequencing primer, 20-mer, bp451-470 5' ACC ACT GCT TTG CCG CCA CC 3'

PR-3s sequencing primer, 20-mer, bp687-668 5' CCG ATG AGA GCG GTG AGC TG 3'

361 atgccctggg ggtgcaccga gacccggcttc cgaccaccgc tcgcccacaac gtcgactggc  
421 tcatatcgag aatgcttgcg gcactgctga accactqctt tgccgcccacc gccccgaaacg  
481 cgcgaaggccc ggccacggcc ggcttagcacc tcttggcgcc gatgccgata aatatgggt  
541 gatataatcac ctggcctga cagcgacttc acggcacgat ggaatgtcgc aaccaaattgc  
601 attgtccgct ttgatgatga ggagagtcat gccactgcta accattggcg atcaattccc  
661 cgcctaccag ctcaccggctc tcatcgccgg tgacctgtcc aaggtcgacg ccaaggcagcc  
721 cggcgactac ttccaccacta tcaccagtga cgaacaccca ggcaagtggc ggggtgggttt

**fabG (isoniazid resistance)**

fabG-F amplification primer, 20-mer, bp56-75 5' CCT CGC TGC CCA GAA AGG GA 3'

fabG-R amplification primer, 20-mer, bp303-284 5' ATC CCC CGG TTT CCT CCG GT 3'

fabG-5s sequencing primer, 20-mer, bp56-75 5' CCT CGC TGC CCA GAA AGG GA 3'

fabG-3s sequencing primer, 20-mer, bp303-284 5' ATC CCC CGG TTT CCT CCG GT 3'

1 agcgcgacat acctgctcg caattcgttag ggcgtcaata caccgcgcac caggactca  
61 ctgcccagaa aqggatccgt catggtcgaa gtgtgctgag tcacaccgac aaacgtcacf  
121 agcgttaaccc cagtgcgaaa gttcccgccg gaaatcgccag ccacgttacg ctcgtggaca  
181 taccgatttc ggccggccg cggcgagacg atagggttgc ggggtgactg ccacagccac  
241 tgaaggggcc aaaccccccattcgtatcccg ttcagtcctg gttaccggaa aaaaacgggg  
301 gatcggtctg gcgatcgac acggctggc tgccgacggc cacaagggtgg ccgtcaccacca

**rpsL/s12 (streptomycin resistance)**

s12-F amplification primer, 20-mer, bp1-20 5' CGG TAG ATG CCA ACC ATC CA 3'

s12-R amplification primer, 20-mer, bp384-365 5' GCA TCA GCC CTT CTC CTT CT 3'

s12-5s sequencing primer, 20-mer, bp1-20 5' CGG TAG ATG CCA ACC ATC CA 3'

s12-3s sequencing primer, 20-mer, bp384-365 5' GCA TCA GCC CTT CTC CTT CT 3'

1   cqqttagatqc caaccatcca gcagctggtc cgcaagggtc gtcgggacaa gatcagtaag  
61   gtcaagacccg cggctctgaa gggcagccccg cagcgctcg gtgtatgcac ccgcgtgtac  
121   accaccactc cgaagaagcc gaactcggcg ctteggaaagg ttgcccgcgt gaagttgacg  
181   agtccaggctcg aggtcacggc gtacattccc ggcgaggccc acaacctgca ggagcactcg  
241   atggtgctgg tgccgcggcg ccgggtgaag gacctgcctg gtgtgcgcta caagatcatc  
301   ccgggttgc tggatacgc ggggtgtcaag aaccgcaaacc aggcacgcag ccgttacggc  
361   gctaagaagg aqaaggqctq atqccacgc aggggccccgc gcccaagcgt ccgttggca

**16S/rrs (streptomycin resistance)**

16S-F amplification primer, 21-mer, bp5-25 5' GGT GAT CTG CCC TGC ACT TCG 3'

16S-R amplification primer, 21-mer, bp147-127 5' CGT CAC CCC ACC AAC AAG CTG 3'

16S-5s sequencing primer, 21-mer, bp5-25 5' GGT GAT CTG CCC TGC ACT TCG 3'

16S-3s sequencing primer, 21-mer, bp147-127 5' CGT CAC CCC ACC AAC AAG CTG 3'

1   cgtgggtgat ctgcccctgca cttccggata agcctgggaa actgggtcta ataccggata  
61   ggaccacggg atgcattgtct tgtggtgaa agcgctttag cgggtgtggaa tgagcccgcg  
121   gcctatcaqc ttgttqgtqa qgtqacg

**embB (ethambutol resistance)**

embB-F amplification primer, 21-mer, bp7761-7781 5' CGG CAA GCT GGC GCA CCT TCA 3'

embB-R amplification primer, 21-mer, bp8040-8020 5' AGC CAG CAC ACT AGC CCG GCG 3

embB-5s sequencing primer, 21-mer, bp7761-7781 5' CGG CAA GCT GGC GCA CCT TCA 3'

embB-3s sequencing primer, 21-mer, bp8040-8020 5' AGC CAG CAC ACT AGC CCG GCG 3

7741 cggcatgcgc cggctgattc cggcaagctg gcgcaccc accctgaccg acggccgtgg  
7801 gatattcggt ttccctgtct ggcattgtcat cggcgcgaat tcgtcgacg acggctacat  
7861 cctgggcatg gcccggatcg ccgaccacgc cggctacatg tccaactatt tccgctggtt  
7921 cggcagcccc gaggatccct tcggctggta ttacaacctg ctggcgctga tgacccatgt  
7981 cagcgacgccc agtctgtgga tgcgcctgcc agacctggac gccaaggctag tatactqact

**pncA (pyrazinamide resistance)**

pncA-F amplification primer, 20-mer, bp1-20 5' ATG CGG GCG TTG ATC ATC GT 3'

pncA-F amplification primer, 20-mer, bp561-542 5' TCA GGA GCT GCA AAC CAA CT 3'

pncA-5s sequencing primer, 20-mer, bp1-20 5' ATG CGG GCG TTG ATC ATC GT 3'

pncA-3s sequencing primer, 20-mer, bp561-542 5' TCA GGA GCT GCA AAC CAA CT 3'

1    atqcgccat tqatcatcq cgacgtgcag aacgacttct gcgagggtgg ctcgctggcg  
61   gtaaccggtg ggcgcgcgt ggcccgccgc atcagcgact acctggccga agcggcgac  
121   taccatcacg tcgtggcaac caaggacttc cacatcgacc cgggtgacca cttctccggc  
181   acaccggact attcctcgtc gtggccaccg cattgcgtca gcggtaactcc cggcgccggac  
241   ttccatccca gtctggacac gtgcggcaatc gaggcggtgt tctacaaggg tgcctacacc  
301   ggagcgatac gcggcttcga aggagtcgac gagaacggca cggccactgct gaattggctg  
361   cggcaacgcg gcgtcgatga ggtcgatgtg gtccgtattt ccaccgatca ttgtgtgcgc  
421   cagacggccg aggacgcggt acgcaatggc ttggccacca gggtgctgggt ggacctgaca  
481   gcgggtgtgt cggccgatac caccgtcgcc gcgctggagg agatgcgcac cggccagcgtc  
541   gacttggttt gcaqctcctq a

**gyrA (fluoroquinilone/ciprofloxacin resistance)**

gyrA-F amplification primer, 20-mer, bp2383-2402 5' CAG CTA CAT CGA CTA TGC GA 3'

gyrA-R amplification primer, 20-mer, bp2702-2683 5' GGG CTT CGG TGT ACC TCA TC 3'

gyrA-5s sequencing primer, 20-mer, bp2383-2402 5' CAG CTA CAT CGA CTA TGC GA 3'

gyrA-3s sequencing primer, 20-mer, bp2702-2683 5' GGG CTT CGG TGT ACC TCA TC 3'

2341 cgaccggatc gaaccggttg acatcgagca ggagatgcag ccaqctaca tcgactatac  
2401 gatgagcgtg atcgtccggcc ggcgcgtgcc ggaggtgcgc gacgggctca agcccgtgca  
2461 tccggccgggtg ctctatgcaa tggtcgattc cggcttccgc ccggaccgca gccacgcca  
2521 gtcgcccccgg tcgggttgcgg agaccatggg caactaccac ccgcacggcg acgcgtcgat  
2581 ctacgcacgc ctgggtgcgc tggcccgagcc ctggtcgctg cgctacccgc tggtgacgg  
2641 ccaggggcaac ttccggctcgc caggcaatga cccaccggcg gqatqagqt acaccqaac  
2701 ccggctgacc ccgttggcga tggagatgt gaggaaatc gacgaggaga cagtgcattt

**23S (macrolide/azithromycin resistance)**

23S-F amplification primer, 20-mer, bp2444-2463 5' CGA AAT TCC TTG TCG GGT AA 3'  
23S-R amplification primer, 20-mer, bp2683-2664 5' GTA TTT CAA CAA CGA CTC CA 3'  
23S-5s sequencing primer, 20-mer, bp2444-2463 5' CGA AAT TCC TTG TCG GGT AA 3'  
23S-3s sequencing primer, 20-mer, bp2683-2664 5' GTA TTT CAA CAA CGA CTC CA 3'

2401 gccccagtaa acggcgggtgg taactataac catcctaagg taqqaatt ctttgtcgag  
2461 taagttccga cctgcacgaa tggcgtaacg acttcccaac tgtctcaacc atagactcg  
2521 cggaaattgca ctacgagtaa agatgctcgtaacg tacgcgcggc aggacgaaaa gaccccgaaa  
2581 ccttcactac aacttggtat tgggttccgg tacggtttgcgt gttaggatagg tgggagactt  
2641 tgaaggcacag acggccagttt gtatqqagtc gtttgtaaaa taccactctg atcgattttgg

To facilitate detection of the sequencing products using real-time fluorescence-based electrophoresis apparatus (for example, a Visible Genetics OpenGene sequencer), at least one of the sequencing primers is preferably labeled with a fluorescent label. The label is selected for compatibility with the sequencing apparatus employed, and may be, for example, fluorescein or a cyanine dye such as Cy5.0 or Cy5.5.

The primers of the invention are suitably packaged in a kit. This kit will contain individually packaged amplification and sequencing primers sets for each

resistance gene to be evaluated by the kit. Thus, the kit of the invention includes at least 4 primers (two amplification and two sequencing primers), and preferably includes the primer sets for a plurality of resistance genes, most preferably the primer sets for all ten resistance genes.

The suitable protocol for the utilization of these primer sets in the evaluation of *M. tuberculosis* in clinical samples utilizes PCR amplification, followed by cycle sequencing. DNA for use in the test is obtained from a sample of sputum (100ul-10ml). The sputum sample is processed according to Standard Infectious Disease/Public Health Laboratory practices (Mycobacteriology Bench Manual, Laboratory Services Branch, December 1997, Ontario Ministry of Health). The sputum sample is homogenized, decontaminated and concentrated. Mycobacterial DNA is prepared directly from a portion of the concentrated cell sediment (100-200ul) using standard DNA extraction methods or commercially available kits.

Amplification of the DNA is performed using the amplification primer sets described above. PCR reagents can be prepared for individual reactions, or may be prepared as a master mix which can be used for multiple tests e.g., 10 PCR reactions. Exemplary combinations of reagents are summarized in the following table.

PCR mix		1 PCR	10 PCRs	final conc. / PCR
genomic DNA	(20ng/ul)	1.0ul		20ng (~0.5fM)
10X PCR buffer I		2.5ul	25.0ul	1X
2.5mM dNTP mix	(1:1:1:1)	2.5ul	25.0ul	250uM
DMSO		1.3ul	13.0ul	5%
Taq DNA polymerase (1U)		0.2ul	2.0ul	1 unit
molecular grade water		16.5ul	165.0ul	
<u>MTB gene primers</u>	(10uM)	<u>1.0ul</u>	10.0ul	10pmol per primer
total volume per PCR		25.0ul		

If the master mix as shown in the column labeled 10 PCRs is utilized, the mastermix contains all the necessary PCR reagents other than the genomic DNA. In this example, 24.0ul of the mastermix is added to a PCR tube, that already contains 1.0ul of genomic DNA, prior to the addition of the mineral oil overlay and placement in the thermocycler.

The genomic DNA preparation utilized must be of sufficient quality and integrity for robust and reproducible PCR. Suitable DNA preparation can be obtained using the Gentra Puregene™ DNA isolation kit. The kit components are appropriate for the isolation of genomic DNA from blood, fresh or frozen tissue, archival material and paraffin-embedded tissue.

Each primer pair is used to amplify a single gene region under the following conditions:

1. Denaturation      94°C      5 minutes      1 cycle
2. Denaturation      94°C      30 seconds
- Annealing      60°C      30 seconds      35 cycles

	Extension	72°C	60 seconds	
3.	Extension	72°C	5 minutes	1 cycle
4.	Hold	6°C		

The temperature change during the cycles of the step 2 is desirably set to ramp at a rate of 1°C/sec.

After amplification, 2.0ul from the 25.0ul PCR is analysed for purity on a 0.8% agarose gel. Samples displaying single PCR product bands can be used directly for sequence analysis. The yield and purity of the PCR product determines the amount to be used in the subsequent cycle sequencing reaction. Comparable verification of sequencing purity is performed on each of the other amplification products.

Sequence analysis is carried out on the amplified product. The basic procedures and conditions are the same for each region. Accordingly, the invention will be exemplified using the rpoB gene.

For initial sequence analysis of rpoB, the rpoB-5s primer should be used. For confirmatory sequence analysis the rpoB-3s primer should be used. For each template to be sequenced, aliquot 3.0ul of each of the nucleotide termination mixes into four separate tubes marked <A>, <C>, <G> and <T> and store on ice until the sequencing mastermix is prepared.

#### Cycle sequencing mastermix

rpoB template	2.0ul
10X VGI Sequenase™ buffer	2.5ul
DMSO	3.5ul

2.5uM dye-sequencing primer	2.0ul
PCR grade water	9.0ul
<u>1:10 diluted Thermosequenase™</u>	<u>3.0ul</u>
total volume	22.0ul

Mix the DMSO and other components in the mastermix well by repeated pipetting (5 times) with a micropipette. Store the mastermix on ice until ready to add to the nucleotide termination mixes.

Add 5.0ul of the mastermix to each of the four marked tubes containing the nucleotide termination mixes.

Add 8.0ul lightweight mineral oil to each of the four marked tubes containing the mastermix and nucleotide termination mixes.

Store on ice until ready to load into the thermocycler.

Parameters for cycle sequencing

1.	Denaturation	94°C	5 minutes	1X
2.	Denaturation	94°C	30 seconds	
	Annealing	60°C	30 seconds	35X
	Extension	72°C	60 seconds	
3.	Extension	72°C	5 minutes	1X
4.	Hold	6°C		

The temperature change during the cycles of the step 2 is desirably set to ramp at a rate of 1°C/sec.

At the end of the cycle sequencing reaction add 6.0ul of the Stop Loading Dye directly to each of the four tubes to stop the sequencing reaction. The sequencing samples are heated at 95°C for 2 minutes and then placed on ice before loading 2.0ul (from a total volume of 14ul) on the Clipper™ sequencer. The remainder of the sequencing reaction can be stored at -20°C for subsequent use.

The Clipper™ sequencer is set-up as described in the *OpenGene Automated DNA Sequencing System User Manual*. Run parameters for the Clipper™ sequencer are 54°C / 1300volts / 0.5sec sampling/35min run/50% laser power. The samples loaded included 2 ul each of the forward and reverse sequencing reaction products for the target gene, differentially labeled, for example with Cy5.0 and Cy5.5 cyanine dye labels. Once the run is completed, the base-called data is analysed by comparison of the test sequence to the rpoB sequence database in GeneLibrarian™. This sequence alignment compares the test sequence to the standard control sequence and allows sequence ambiguities to be assessed. Once edited the test sequence can be screened for antibiotic resistance-associated mutations using GeneLibrarian™.

Testing for multiple types of antibiotic-resistance mutations can be carried out using a hierarchical assay, as summarized in Fig. 2. At present molecular biological methods for the detection of *M. tuberculosis* are only performed on AFB smear-positive sputum samples. These methods serve as confirmatory tests for the presence of *M. tuberculosis*. In addition to these molecular biological methods, the culture-based procedures for *M. tuberculosis* detection (BacTec liquid culture, agar plate and slant cultures) are performed in parallel. AFB smear-negative sputum samples are processed with only the culture-based detection procedures (Figure 1).

In the present invention both AFB smear-positive and smear-negative sputum samples can be processed using both culture-based and molecular biological methods. A

limitation of the AFB stain methodology is its limit of detection. If a sputum sample has a mycobacterial concentration of less than 5000 bacteria/ $\mu$ l the AFB stain will be negative. In addition to this is the observation that the decontamination procedure used to prepare the sputum sample usually kills 10-20% of the mycobacteria present. This would suggest that two-thirds of the AFB smear-negative samples potentially contain mycobacteria. In practice 10-20% of the AFB smear-negative samples are culture-positive for *M. tuberculosis* (Ontario Public Health Laboratory). This level of mycobacteria is easily detected by molecular biological methods and is therefore incorporated in the present invention.

The hierarchy proposed incorporates tests that specifically detect *M. tuberculosis* (*rpoB*), detect mutations in genes associated with resistance to the "first-line" antibiotics used to treat *M. tuberculosis* infections (*rpoB*, *katG*, *rpsL/s12*, *23S*, *PR*, *embB*, *pncA*, *gyrA*) and detect other species of mycobacteria (*23S*) in the absence of *M. tuberculosis* (Figure 2). Group I analyses are performed before both Group II and Group III. Group I analysis will provide information on the antibiotic resistance status to rifampin (*rpoB*), isoniazid (*katG*), streptomycin (*rpsL/s12*) and azithromycin (*23S*). In addition the *rpoB* amplification indicates the presence of *M. tuberculosis* and in the absence of *rpoB* amplification the *23S* sequence allows identification of most of the clinically relevant mycobacterial species. Group II analysis provides information on antibiotic resistance mutations in the "second-line" antibiotics used to treat *M. tuberculosis* infections namely, isoniazid (*PR*), ethambutol (*embB*), pyrazinamide (*pncA*) and ciprofloxacin (*gyrA*). Group III contains gene targets in which mutations associated with antibiotic resistance are infrequently found. This protocol permits specific gene targets to be examined according to the local treatment procedures since the both antibiotics used to treat *M. tuberculosis* infections, and thus the associated antibiotic resistance mutation patterns, vary geographically. As shown in Figure 2 the culture-based methods are performed in parallel. The molecular biological methods would permit the identification of *M. tuberculosis* from both AFB smear-

positive and smear-negative sputum samples and further provide information on the antibiotic resistance profile of these samples well in advance of current culture-based methods. This information would be crucial to the initiation of appropriate and effective antibiotic treatment regimens for *M. tuberculosis* infections.

#### Examples

A pool of DNA samples from antibiotic-sensitive *M. tuberculosis* isolates was obtained from the LCDC, Health and Welfare Canada, Ottawa, Ontario. Wild-type sequence traces, for all gene targets known to harbor mutations in antibiotic-resistant *M. tuberculosis*, were generated.

A panel of DNA samples from five phenoptypic streptomycin-resistant *M. tuberculosis* isolates was obtained from the Public Health Laboratory, Ontario Ministry of Health, Toronto, Ontario. These DNA samples were examined for antibiotic resistance-associated mutations in all 10 antibiotic gene targets listed above. Streptomycin resistance-associated mutations were detected in the rpsL/s12 gene in four isolates. Parallel antibiotic resistance-associated mutations in the rpoB (rifampin), katG (isoniazid), PR (isoniazid), embB (ethambutol), pncA (pyrazinamide) and gyrA (ciprofloxacin) genes were also identified which underscores the importance of examining all the gene targets for first-line antibiotics used in the treatment of *M. tuberculosis*. A summary of the results is shown in Table 1.

The following references are cited herein and are incorporated herein by reference.

- <sup>a</sup> DL Williams et al. (1994). Characterisation of rifampin resistance in pathogenic mycobacteria. *Antimicrob Agents Chemother* 38: 2380-2386.
- <sup>b</sup> WH Haas et al. (1997). Molecular analysis of katG gene mutations in strains of *Mycobacterium tuberculosis* complex from Africa. *Antimicrob Agents Chemother* 41: 1601-1603.
- <sup>c</sup> S Sreevatsan et al. (1997). Analysis of the oxyR-ahpC region in isoniazid-resistant and -susceptible *Mycobacterium tuberculosis* complex organisms recovered from diseased humans and animals in diverse localities. *Antimicrob Agents Chemother* 41: 600-606.
- <sup>d</sup> A Telenti et al. (1994). Genotypic assessment of isoniazid and rifampin resistance in *Mycobacterium tuberculosis*: a blind study at the reference laboratory level. *Antimicrob Agents Chemother* 35: 719-723.
- <sup>e</sup> C Katsukawa et al. (1997). Characterisation of the rpsL and rrs genes of streptomycin-resistant clinical isolates of *Mycobacterium tuberculosis* in Japan. *J Appl Microbiol* 83: 634-640.
- <sup>f</sup> C Katsukawa et al. (1997). Characterisation of the rpsL and rrs genes of streptomycin-resistant clinical isolates of *Mycobacterium tuberculosis* in Japan. *J Appl Microbiol* 83: 634-640.
- <sup>g</sup> MA Lety et al. (1997). A single point mutation in the embB gene is responsible for resistance to ethambutol in *Mycobacterium smegmatis*. *Antimicrob Agents Chemother* 41: 2629-2633.
- <sup>h</sup> A Scorpio et al. (1997). Characaterisation of pncA mutations in pyrazinamide-resistant *Mycobacterium tuberculosis*. *Antimicrob Agents Chemother* 41: 540-543.

- <sup>j</sup> C Xu et al. (1996). Fluoroquinilone resistance associated with specific gyrase mutations in clinical isolates of multidrug-resistant *Mycobacterium tuberculosis*. *J Infect Disease* 174: 1127-1130.
- <sup>j</sup> KA Nash et al. (1995). Genetic basis of macrolide resistance in *Mycobacterium avium* isolated from patients with disseminated disease. *Antimicrob Agents Chemother* 39: 2625-2630.

2025 RELEASE UNDER E.O. 14176

Table 1.

gene (antibiotic)	OPH#1 bp/codon/aa	OPH#2 bp/codon/aa	OPH#3 bp/codon/aa	OPH#4 bp/codon/aa	OPH#11 bp/codon/aa
rpoB (flampin)	cac526tac, His526Tyr	tgc553tg, Ser553Leu	cac526gac, His526Asp	tgc553tg, Ser553Leu	wt
katG_1 (isoniazid)	agc513acc, Ser513Thr	agc513acc, Ser513Thr	agc513acc, Ser513Thr	wt	wt
oxyR-ahpC PR (isoniazid)	g541a	wt	wt	wt	g541a
fabG (isoniazid)	wt	wt	wt	wt	wt
rpsL/s12 (streptomycin)	wt	aag43agg, Lys43Arg	aag43agg, Lys43Arg	aag88agg, Lys88Arg	aag43agg, Lys43Arg
16S/rrs (streptomycin)	wt	wt	wt	wt	wt
embB (ethambutol)	wt	gtc292tc, val292phe	wt	wt	wt
pncA (pyrazinamide)	tcc65tct, Ser65Ser	wt	att133aat, Ile133Asn	wt	tcc65tct, Ser65Ser
gyrA (ciprofloxacin)	agc95acc, Ser95Thr				
23S (aztreonam)	wt	wt	wt	wt	wt

Figure 1.






Figure 2



PRINT OF DRAWINGS  
AS ORIGINALLY FILED

United States Patent & Trademark Office  
Office of Initial Patent Examination – Scanning Division



Application deficiencies were found during scanning:

- Page(s) \_\_\_\_\_ of \_\_\_\_\_ were not present  
for scanning. (Document title)
- Page(s) \_\_\_\_\_ of \_\_\_\_\_ were not present  
for scanning. (Document title)
- Scanned copy is best available.

**This Page Blank (uspto)**